FDA Webview
X
about-us-banner

FDA Related News

Home / Articles / FDA Related News
Federal Register

Guide on Trial Master Protocols During Covid-19

Federal Register notice: FDA makes available a final guidance entitled Covid 19: Master Protocols Evaluating Drugs and Biological Products for Treatme...

Federal Register

Regulatory Review Determined for Zolgensma

Federal Register notice: FDA determines for patent extension purposes the regulatory review period for Novartis Zolgensma.

FDA General

Bill Would Create New Health Advanced Research Agency

Reps. DeGette and Upton propose language for a Cures 2.0 bill circulating in Congress to create the Advanced Research Projects Agency-Health sought by...

Human Drugs

ODAC Recommends Deferring Action on Retifanlimab

The Oncology Drug Advisory Committee recommends that FDA not take action to approve Incytes retifanlimab for squamous carcinoma of the anal canal and ...

Biologics

Genentech BLA for Wet AMD Implant Submitted

FDA accepts for priority review a Genentech BLA for its Port Delivery System with ranibizumab for treating wet age-related macular degeneration.

Federal Register

Workshop on Leukoencephalopathy Trials

Federal Register notice: FDA announces a 9/21 public workshop entitled Considerations for Progressive Multifocal Leukoencephalopathy Clinical Trial De...

Human Drugs

Breakthrough Therapy Designation for 2 New Alzheimers Drugs

FDA grants breakthrough therapy designations to Alzheimers drugs being developed by Lilly and Eisai/ Biogen.

Human Drugs

Sterile Drug Compounding Deficiencies at Roger Williams Center

FDA issues a notice of violation to the Roger Williams Medical Center Oncology Pharmacy Clinic relating to deficiencies in the preparation of compound...

Medical Devices

Oticon PMA Approved for Cochlear Implant

FDA approves an Oticon Medical PMA for the companys Neuro System, a cochlear implant for treating individuals 18 years or older with bilateral severe-...

FDA General

Ex-FDAer Laughren Joins Cybin Advisory Board

Retired FDA psychiatry products director Thomas Laughren joins Cybin as a clinical advisory board member.